Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116532 · ClinicalTrials.gov registry record · Phase 4
Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)
A Phase 4 study of Obsessive - Compulsive Disorder, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00116532 is a Phase 4 study of Obsessive - Compulsive Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00116532, a Phase 4 study of Obsessive - Compulsive Disorder, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the efficacy of Escitalopram in the treatment of obsessive compulsive disorder and to determine the optimal treatment dose.
Conditions Studied
Interventions
- DRUG Escitalopram
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - OCD Clinic - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-10 |
| Est. Completion | 2007-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116532
The ClinicalTrials.gov registry entry for NCT00116532 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Escitalopram is the first listed.
NCT00116532 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00116532 about?
NCT00116532 is a clinical study titled "Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)". The purpose of this study is to assess the efficacy of Escitalopram in the treatment of obsessive compulsive disorder and to determine the optimal treatment dose.
What is the current status of trial NCT00116532?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2002-10. Estimated completion is 2007-02.
What conditions does trial NCT00116532 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT00116532?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00116532?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00116532 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder
ACTIVE NOT RECRUITING · Phase 4
-
Treatment of Obsessive-Compulsive Disorder
COMPLETED · Phase 4
-
Predicting Treatment Response in Patients With OCD
COMPLETED · Phase 4
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
-
Mechanisms of Exposure Therapy for OCD
RECRUITING · NA
-
Using Personalized Assessments in the Treatment of Childhood OCD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.